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Summary Tumours develop through the accumulation of genetic alterations associated with a progressive increase of the malignant
phenotype. In lung cancer, chronic exposure of bronchial epithelium to carcinogens in cigarette smoke may lead to multiple dysplastic and
hyperplastic lesions scattered throughout the tracheobronchial tree. Little is known about the genetic alterations in such lesions. This study
was carried out to examine cyclin Dl (CCND1) and retinoblastoma (RB1) gene expression in the bronchial epithelium of patients with lung
cancer. Lung tumours and their corresponding tumour-free resection margins from 33 patients who underwent resection of non-small-cell lung
cancer (NSCLC) were examined by immunostaining with monoclonal antibodies against cyclin Dl (DCS-6; Novocastra) and pRb (NCL Rb-1;
Novocastra). Examination of the resection margins revealed four carcinomas in situ, 19 hyperplasias and ten sections showing apparently
normal bronchial epithelium. A control group of patients, without lung tumours and who had never smoked, revealed no orweakcyclin Dl and
positive pRb staining within bronchial epithelia. Increased cyclin Dl and diminished pRb expression were found in 76% (n = 25) and 27%
(n = 9) of the resection margins respectively, and in 12% (n = 4) both cyclin Dl and pRb expression were altered. In the corresponding
tumours, 48% (n = 16) were normal, while altered expression was found for cyclin Dl in 33% (n = 11), pRb in 27% (n = 9) and both in 9%
(n = 3) of cases. It appears that altered expression of cyclin Dl and pRb is an early event in NSCLC development in almost half of cases
analysed. Further investigations are needed to determine the significance of immunostaining of bronchial specimens in individuals at risk of
lung cancer, with the possibility that the observations are of importance in the early diagnosis of NSCLC.
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Lung cancer has become a worldwide problem with a greater than
tenfold increase in incidence of reported disease since 1930.
Chronic exposure to bronchial irritants appears to lead toepithelial
changes, scattered throughout the tracheobronchial tree (Auerbach
et al, 1962a,b, 1975). Patients with lung cancer have a much
greater frequency of epithelial hyperplasia in main bronchi
(>90%) compared with patients (10%) who have never smoked
(Auerbach et al, 1961). The best evidence for an association
between carcinoma in situ and invasive carcinomaprobably comes
from sputum cytology from uranium miners, which showed
increasingly abnormal epithelial cells as the patients progressed
towards invasive lung tumours (Saccomanno et al, 1974). These
results suggest that the whole tracheobronchial tree is affected by
carcinogen exposure. Cells with genetic lesions resulting in a
growth advantage are likely to replace the epithelium ofthe whole
tracheobronchial tree and, in the case ofadditional genetic events,
may show invasive growth (Thiberville et al, 1995).
Cyclins, through the targeting of cyclin-dependent kinases
(CDKs), control progression of the cell during the various stages
of the cell cycle. With respect to cancer, perhaps the most impor-
tant of these proteins is cyclin Dl. Cyclin D1-CDK4 complexes
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appear to act by phosphorylating and inactivating the retino-
blastoma-suppressor protein (pRb). This results in the release,
from pRb, of a bound transcription factor E2F. E2F complexes
then activate genes necessary for cell division. The p16 protein
suppresses the process by competitively binding to the CDK4
molecule. Component genes ofthis control pathway are frequently
mutated, amplified or deleted in malignant cells (for review see
Hirama and Koeffler, 1995). Overexpression of cyclin Dl has
been reported in epithelial tumours, such as colorectal, head and
neck, oesophageal, breast, uterus, hepatocellular and lung carci-
nomas, melanomas and sarcomas (Zhang et al, 1993; Bartkova et
al, 1994 a,b, 1995; Gillett et al, 1994; Nishida et al, 1994;
Michalides et al, 1995; Naitoh et al, 1995; Nakagawa et al, 1995).
We have recently reported cyclin Dl overexpression in 43% of
non-small-cell lung cancers (NSCLC) (Betticher et al, 1996). The
overexpression was caused by CCNDJ amplification in only 17%
ofcases. However, in all cases showing overexpression and infor-
mative for a HaeIII polymorphism (Heighway, 1991), an imbal-
ance in allele-specific expression was observed. This suggested
specific up-regulation of one CCNDI allele and was consistent
with the gene having a key function in lung carcinogenesis.
Cyclin DI andpRb arepartofacomplicated networkthatgoverns
cell proliferation. During the last years new proteins (p16, p15, p57,
p27 and p2l) were reported to possess inhibitory activity on the
cyclin-kinase complexes (Hirama and Koeffler, 1995). However,
since cyclin DI-CDK4-pRb stimulates the proliferation and func-
tion before the commitment point, such a deregulation might have
primordial importance in malignant growth. We were, therefore,
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Table 1 Association of epithelial alterations in the resection margins of NSCLC and patient/tumour characteristics
(chi-square test)
Altered epithelium Normal epithelium P.value
(hyper-, dysplasia, carcinoma in situ)
Number of patients 23 10
Sex 0.75
Male 19 8
Female 4 2
Age 0.01
< 60 years 12 0
260 years 11 10
Histology 0.73
Squamous carcinoma 18 8
Non-squamous carcinoma 5 2
Differentiation 0.06
Good-moderate 11 9
Poor 12 1
Necrosis 0.97
Marked 10 5
Scant 13 5
Lymphocytic infiltration of the tumour 0.50
Prominent 3 3
Moderate-poor 20 7
Table 2 Cyclin Dl immunostaining in breast cancer, *normal lung epithelium
bronchiectasis, and from NSCLC with their respective resection margins
ifrom patients who underwent lung transplantation for emphysema, fibrosis and
Tissue/tumour/cell line Number of samples examined Cyclin Dl immunostaining paftern
Nil Weak Mod-strong
N C N+C
Breast cancer 15 9 - 6
Normal epithelium* 6 3 3 - - -
Cell lines
SKUT-1 -B (leiomyosarcoma) - - - +
MDA-MB-231 (breast cancer) - - - + -
NSCLC
Tumour 33 6 16 - 3 8
Resection margin 33 1 7 20 5
N, nuclear; C, cytoplasmic; N+C, both.
interested to study whether an alteration of CCNDI and RBI gene
expression would occurearly in lung tumour development.
PATIENTS AND METHODS
Patient characteristics and specimens
Tumour and resection margin samples were obtained from 33
consecutive patients [27 men, six women, median age 63 years
(range 39-77 years)] who underwent resection of NSCLC at
the Regional Cardiothoracic Centre, Wythenshawe Hospital,
Manchester, UK. They had received no chemo- or radiotherapy
before surgery. All tumours were classified according to the stan-
dard WHO criteria (1981). The degree oflymphocytic infiltration,
presence of necrosis and vascular infiltration were determined
histologically. Eleven of 31 patients with survival data are alive
with a median follow-up of70 months (range 3-77 months).
The specificity ofimmunostaining was determined for 14 breast
cancer specimens as reported previously (Betticher et al, 1996), in
two cells lines (SKUT-1-B and MDA-MB-231) known to over-
express cyclin Dl, and in six lung specimens frompatients with no
lung tumours and who had never smoked. In these patients, lung
transplantation was performed because of emphysema (n = 3),
interstitial pulmonary fibrosis (n = 2) and bronchiectasis (n = 1).
Immunohistochemistry
The immunohistochemistry was performed as described previ-
ously (Gillett et al, 1994; Geradts et al, 1994; Betticher et al,
1996). Briefly,4-gm formalin-fixed paraffin sections from tumour
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Figure 1 (A-C) Cyclin Dl expression in (A) normal epithelium of lung
without tumour (cyclin DI-); (B) hyperplastic epithelium of a lung with
NSCLC (cytoplasmic cyclin Dl overexpression); (C) squamous lung tumour
(cyclin Dl nuclear and cytoplasmic overexpression); (D-E) retinoblastoma
expression in (D) carcinoma in situ (pRb+) and (E) lung tumour (pRb-)
(breast cancer, resection margins with respective NSCLC) and
lung specimens were air dried on 2% APTS (Sigma, Poole, UK)
coated slides. After dewaxing in xylene, the sections were treated
for 15 min with 300 ml of methanol and 10 ml of hydrogen
peroxide to block endogenous peroxidase and rinsed thoroughly in
water. They were then placed in citrate buffer, boiled twice in a
microwave, washed with water and placed in Tris buffer (pH 7.6).
After incubation in 1:100 goat serum for 20 min at room tempera-
ture, they were placed either in 1% bovine serum albumin (BSA)
and 1:100 mouse monoclonal cyclin Dl antibody (DCS-6;
Novocastra, Newcastle, UK) or in 1% BSA and 1:50 mouse mono-
clonal pRb antibody (NCL-Rbl; Novocastra) overnight at room
temperature. After two washes with Tris buffer, they were incu-
bated in 1:100 biotinylated goat anti-mouse/rabbit IG (Dako,
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Table 3 Cyclin Dl and retinoblastoma expression in lung tumours and epithelia of the resection margins
Epithelia in resection margins Tumour
Histology Cyclin Dl pRb Histology Cyclin DI pRb
(N/H/Ca)
Cytopi Nuci Cytopi Nuci
N 0 0 * Sqca 0 0 0
N 0 0 0 Sq ca 0 0 9
N *0 0 Sq ca 0 0 0
N 0 0 0 Sqca 0 0 0
N *0 0 Sqca 0 0 0
N *0 0 Sqca 0 0 0
N *0 0 Adenoca O O O
N 0 0 0 Adenoca 0 0
N 0 0 0 Sqca 0 0 0
N 0 0 0 Sqca 0 0 0
H 0 0 0 Sq ca 0 0 0
H 0 0 0 Sqca 0 0 0
H 0 0 0 Sqca 0 0 0
H 0 * * Sqca *0 0
H *0 0 Sqca 0 0 0
H 0 0 0 Sqca 0 0 0
H 0 0 0 Sqca 0 0 0
H 0 0 0 Sq ca 0 0 0
H 0 0 * Sqca 0 0 0
H 0 0 0 Adenoca 0 0 0
H 0 0 0 Adenoca 0 0 0
H 0 0 0 Sq ca 0 0 0
H 0 0 0 Sqca 0 0 0
H 0 0 0 Sqca 0 0 0
H 0 0 0 Sqca 0 0 0
H 0 0 0 Sqca 0 0 0
H 0 0 0 Sqca * *
H 0 0 0 Large-cell ca 0 0 0
H 0 0 0 Carcinoid 0 0 0
Ca 0 0 0 Sqca 0 0 0
Ca 0 0 0 Adenoca 0 0 0
Ca 0 0 0 Sqca 0 0 0
Ca 0 0 0 Sqca *0 0
*, positive staining (pathological for cyclin Dl, normal for pRb); 0, negative staining (normal for cyclin Dl, pathological for
pRb); N, normal; H, hyperplasia and dysplasia; Ca, carcinoma in situ.
Glostrup, Denmark) for 30 min, washed twice with Tris, incubated
in a 1:100 solution of streptavidin biotin complex for 30 min at
room temperature, rewashed in Tris buffer and placed in
diaminobenzedine (10 mg 10 ml-1) for 10 min, counterstained with
haematoxylin, washed in water, cleared, dehydrated and mounted.
Cyclin DI and pRb staining was examined according to the inten-
sity ofthe majority ofcells. The slides were assessed blind in two
series; thus, the pathologist did not know the results of cyclin DI
expression when examining the pRb staining. Positive and nega-
tive control experiments were performed for each tumour series.
For cyclin DI, two categories of staining were used: nil-weak
(negative) and moderate-strong (positive). For pRb, specimens
were considered negative when control cells (lymphocytes and
endothelial cells) were positive, but nuclei of tumour or epithelial
cells in the resection margins showed no staining.
Statistical analyses
Patients were placed into two groups according to their cyclin
DI/pRb expression, e.g. normal: pRb+, cyclin Dl- v pRb- and/or
cyclin D1+. Associations of group membership with other patient
and tumour characteristics were made with chi-square tests for
categorical features and Mann-Whitney U-tests for continuous
ones. Kaplan-Meier survivor function estimates were used and
simple comparisons between the two groups were made with the
log-rank test.
RESULTS
NSCLC and resection margins
Thirty-three patients with operable NSCLC were examined for
epithelial precancerous lesions in their respective resection
margins. According to the WHO classification (1981), the histo-
logical subtypes were as follows: 26 squamous carcinomas, five
adenocarcinomas, one large-cell carcinoma and one bronchial
carcinoid. The resection margin specimens free from tumour
showed carcinoma in situ in four, epithelial hyperplasia or
dysplasia in 19 and apparently normal epithelium in ten cases.
Interestingly, patients below 60 years (P = 0.01) and with poor
tumour differentiation (P = 0.06) appeared to be associated with a
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Figure 2 Survival of patients according to the cyclin Dl and pRb expression
in the tumour (P = 0.20).- Normal cyclin Dl and pRb expression; * cyclin
Dl overexpression and/or absent pRb
greater incidence of hyperplastic and dysplastic epithelial alter-
ations in the resection margins (Table 1). No further associations
referring to tumour necrosis, histological subtype or gender distri-
bution with epithelial alterations were found.
Cyclin Dl overexpression
The level of cyclin Dl expression in the resection margin was
assessed by immunohistochemical staining [monoclonal antibody
DCS-6 (Lukas et al, 1994; Bartkova et al, 1994c)] and the results
compared with cyclin Dl staining ofthe corresponding tumour. To
ascertain normal cyclin DI levels (physiological compared with
pathological levels ofthe protein), samples ofbreast cancers, two
cell lines (SKUT-1-B and MDA-MB-231) known to overexpress
cyclin DI and lung specimens without carcinoma were investi-
gated (Table 2). Forty per cent of breast tumours (6/15) showed
nuclear cyclin Dl immunostaining. Both cell lines revealed cyclin
Dl overexpression localized exclusively to the cytoplasm, and
finally, bronchial epithelia from control patients with emphysema,
bronchiectasis or interstitial pulmonary fibrosis was either nega-
tive or weakly positive for cyclin Dl (Figure 1A).
In lungs of patients with NSCLC, the epithelial cells in the
resection margins were positive in 25 cases (76%) (Table 3 and
Figure iB). In general, dysplastic cells revealed strong positivity,
while hyperplasia had more frequent moderate positivity. In some
cases, strong positivity was also found in epithelial cells of appar-
ently normal epithelium. In all cases, cyclin Dl was localized to
the cytoplasm, while concurrent nuclear staining was seen in five
of25 positive cases. In the tumours, 11 (33%) were positive and 22
specimens (66%) showed no or little staining comparable with the
pattern seen in normal tissue. Cytoplasmic cyclin Dl localization
was seen in all tumours and additional nuclear staining in 8/11 of
cases (Figure IC). The frequency of tumours staining in this inde-
pendent series (patients from UK) is similar to that reported in our
earlier (Swiss patients) study (Betticher et al, 1996). Inflammatory
and endothelial cells, and fibroblasts were uniformly negative.
Serous glands showed strong cytoplasmic positivity for cyclin
D1 staining.
Retinoblastoma protein expression
Expression of the pRb protein in tumours was assessed using a
mouse monoclonal pRb antibody that has been reported to bind to
the pRb protein independently of the phosphorylation status and
the presence of certain point mutations (Bartek et al, 1992). The
immunostaining of the non-cancerous lung tissue showed typical
staining patterns. In particular, the pRb protein was present in the
nuclei of some, but not all, bronchial epithelial cells, stromal cells
(especially lymphocytes and endothelial cells) and bronchial glan-
dular and ductal cells. The examination of epithelial cells in the
resection margin revealed the presence ofthe pRb protein in 24/33
specimens. No staining was seen in nine resection margins (27%).
In the tumour, 17 (52%) were strongly positive for pRb staining,
seven (21%) were moderately positive and nine tumours (27%),
including two cases with aberrant pRb expression in the resection
margin, were negative for pRb expression (Table 3 and Figure
lD-E). Nuclear pRb subcellular localization was observed in all
cases, although weak concomitant cytoplasmic staining was seen
in some specimens.
Taken together, in the normal control tissues, low cyclin Dl
expression and pRb nuclear staining was seen. Conversely, altered
expression was found in 30 epithelia of resection margins (91%)
and in 17 NSCLC (52%) (Table 3). In view of the presumed
nuclear cyclin D1-pRb interaction, the analysis was made for
cyclin Dl nuclear staining only; 14 resection margins (42%) and
15 tumours (46%) revealed altered expression (Table 3). No resec-
tion margin and only two tumours had simultaneous nuclear
CCNDJ and RBI deregulation.
Cyclin D1/RB1 staining in correlation with pathology
and clinical outcome
We found no obvious correlation between cyclin DI and/or pRb
protein expression and specific pathological parameters of the
NSCLC examined. The overall survival (Figure 2) tends to corre-
late with cyclin DI and/or pRb deregulation in the tumour; the
median survival ofpatients with normal cyclin D1 andpRb protein
expression was 3.5 years compared with 1.3 years when cyclin Dl
and/or the pRb protein was abnormal (P = 0.20).
DISCUSSION
Acquisition ofa malignant phenotype follows the accumulation of
multiple genetic changes by a cell. These may include deletions,
point mutations, chromosomal translocations or gene amplifica-
tions. Support for this view is found in colon carcinoma is which
a typical sequence of genetic changes has been described
(Vogelstein et al, 1988). In NSCLC, it is reasonable to assume that
the bronchial epithelium is progressively damaged by chronic
carcinogen exposure. In this study, 23/33 epithelia showed histo-
logical alterations, including hyperplasia and carcinoma in situ,
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and interestingly, these changes were associated with low age and
poor tumour differentiation.
Mutation of KRAS2 seems to be an early event in a third of lung
adenocarcinomas (Rodenhuis et al, 1987). Other genetic lesions
have been reported in NSCLC, such as interference with RBI (Xu
et al, 1991; Reissmann et al, 1993; Higashiyama et al, 1994; Xu et
al, 1994; Geradts et al, 1994; Xu, 1995) compared with normal
tissues (Cordon-Cardo and Richon, 1994) and TP53 gene (Chiba
et al, 1990) mutations, as well as overexpression of the ERB-B2
(Carbone and Minna, 1992) and CCNDI (Schauer et al, 1994;
Shapiro et al, 1995; Betticher et al, 1996) genes. However, little is
known about their presence in precancerous lesions and their
significance in tumorigenesis. Overexpression of cyclin DI at
early stages of tumour development has been reported recently in
several studies on premalignant skin lesions in mice (Robles and
Conti, 1995), in human carcinoma in situ of the breast (Weinstat-
Saslow et al, 1995), in familial adenomatous polyposis of the
colon (Zhang et al, 1996), in premalignant epithelia of patients
with head and neck tumours (Izzo et al, 1996) or gastric and
oesophageal cancer (Arber et al, 1996). In mice, cyclin Dl was
found to be overexpressed in precancerous lesions, including
small incipient papillomas, after induction by a two-stage carcino-
genesis protocol (Robles and Conti, 1995). Normal and hyper-
proliferative skin were negative for cyclin Dl, and the intensity of
cyclin D1 staining was associated with the grade of dysplasia.
Another study (Weinstat-Saslow et al, 1995) reports on a large
number ofhuman breast biopsies, in which cyclin DI overexpres-
sion was found in 87% of ductal carcinoma in situ and in 83% of
invasive breast carcinoma lesions, but rarely in normal tissue.
During the multistep evolution ofcancers, the normal inhibitory
role of pRb in the cell cycle progression can be abrogated by
various mechanisms, including increased levels of cyclin Dl,
direct loss ofpRb function or othermechanisms, not yet identified,
that might override pRb. According to this model and at the
simplest level, there might be little selective advantage in the
coincident occurrence within a tumour cell of up-regulation of the
cyclin Dl gene and loss of Rb function. Indeed, a strong associa-
tion between altered cyclin Dl and pRb expression has been
reported in oesophageal tumours (Jiang et al, 1993). Tumours and
cell lines that had CCNDI amplification and cyclin Dl overex-
pression exhibited normal levels ofexpression ofpRb. In contrast,
tumours and cell lines that did not appear to express the pRb did
not show CCNDI amplification and expressed only low levels of
cyclin Dl. Similarly, in lung cancer, SCLC cell lines with low or
undetectable cyclin Dl expression had no pRb staining. In
contrast, in all NSCLC cell lines studied, cyclin Dl was over-
expressed, while the expression of the pRb protein appeared
normal (Schauer et al, 1994).
In this study on primary NSCLC tumour specimens, such a
strong association was not found. Of the 17 tumours showing
abnormal cyclin Dl or pRb expression, three showed apparent
overexpression of CCNDI and no detectable RBI expression,
while 14 showed abnormal expression of one or other gene.
However, it is perhaps worth noting that positive staining for pRb
does not necessarily reflect a functional retinoblastoma protein.
Indeed, the antibody used binds to pRb independently ofthe pres-
ence ofsome point mutations (Bartek et al, 1992). Considering the
resection margins, the majority (21/33, including 8/10 histologi-
cally normal epithelia) showed normal pRb but elevated cyclin Dl
levels. Cells in four margins demonstrated aberrant expression of
both genes (Table 3). But most interestingly, epithelial cells from
only three margins showed apparently normal levels of both
proteins. One explanation for the observation that CCNDI and
RBI expression is perturbed in epithelial cells from the tumour-
free margins is that alterations ofthese key cell cycle control genes
can occur at a very early stage in the development of lung cancer.
Consistent with our earlier study of resectable NSCLC
(Betticher et al, 1996), in the majority of tumours analysed, the
cyclin DI protein detected in the sections was predominantly cyto-
plasmic. This pattern was also the predominant mode of staining in
cells from the resection margins. Cytoplasmic staining has been
reported in a number ofother malignant tissues (Gillett et al, 1994;
Nakamura et al, 1994; Banno et al, 1994; Zhang et al, 1994;
Swerdlow et al, 1995; Kuroda et al, 1995). It has been suggested
that this pattern might be artifactual with only nuclear staining
reflecting true overexpression of CCNDJ. While this possibility
cannot be completely ruled out, we feel it is insufficient to explain
the data; Our initial study (Betticher et al, 1996) combined an
analysis of CCNDJ amplification, immunohistochemistry and a
determination of allele-specific expression levels. The predomi-
nant mode of staining in NSCLC cells was cytoplasmic. In all
cases in which elevated protein levels were observed, an imbal-
ance in allele-specific mRNA levels was seen. A control series of
breast tumours was also analysed, and in these samples the
predominant mode of staining was, as expected, nuclear. We there-
fore feel that the cytoplasmic staining observed reflects elevated
levels of cyclin DI within the cells. Furthermore, immunhisto-
chemistry of cell lines (SKUT-l-B and MDA-MB-231) known to
overexpress cyclin Dl at the RNA and protein levels (Kurzrock et
al, 1995) revealed strong, exclusively cytoplasmic, staining.
This raises questions as to why the cyclin Dl protein should be
localized in the cytoplasm, if its main role in promoting growth is
to phosphorylate pRb, thereby facilitating cell cycle progression?
Alternate splicing of the CCNDI gene has been reported
(Betticher et al, 1995). It is not inconceivable that alternate cyclin
Dl proteins produced from such transcripts might have distinct
function and subcellular localizations and yet still be recognized
by DCS-6.
Strong cytoplasmic cyclin Dl staining was also present in a
great number of serous glands. Bronchial glands proliferate in
response to chronic damage of the tracheobronchial epithelium.
Since glandular as well as basal cells are able to differentiate into
adult epithelium, it has been hypothesized that any cell capable of
division has the potential to produce hyperplastic, metaplastic and
neoplastic lesions composed of cells that may differ phenotypi-
cally from the parent cell(s) (McDowell and Beals, 1986).
However, the exact significance of glandular tissue in carcino-
genesis and, in particular, the implication of cytoplasmic cyclin
Dl overexpression in these cells and resection margins remain to
be established.
Taken together, normal cyclin DI and pRb expression was
found in only three resection margin epithelia in which the corre-
sponding tumours also showed no pathological expression ofthese
genes. In six resection margins, identical abnormal expression
patterns were seen as in the corresponding tumour (Table 3).
Finally, three resection margin specimens with cyclin Dl overex-
pression had additionally altered pRb expression in their tumour.
In contrast, the finding that 13 bronchial epithelia with abnormal
expression (cyclin Dl overexpression or pRb negativity) had
normal immunostaining in their tumours, while at first sight
appearing perplexing, might in fact be explained by the evolu-
tionary history ofthe patients' condition.
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Kishimoto et al (1995) have reported loss of heterozygosity
(LOH) for 9p (the location of a third G1 control gene CDKN2,
which encodes p16) in preneoplastic NSCLC lesions. Surprisingly,
when multiple, geographically and morphologically distinct
lesions were examined, LOH for the same 9p allele was reported.
There are several possible explanations for these results, including
the preferential loss of one parental region of 9p, in the develop-
ment of malignant disease. However, as discussed by Sidransky
(1995), this result might reflect an initial lesion in just one cell in
these patients. As these cells proliferate, they become geographi-
cally disseminated. Subsequent genetic changes in the separated
lesions of this clonal population would then occur independently,
perhaps leading to histologically distinct preneoplastic areas. Such
a model of clonal evolution may help to explain our results. At
least in the cases in which the tumours and margins give different
pathological staining patterns for cyclin Dl and pRb, we would
have to conclude that alteration of these genes, although perhaps
an early event in the development of the disease, was not the
primary neoplastic lesion but was linked to further tumour devel-
opment. We would therefore hypothesize an initial lesion in a
target cell, which underwent a clonal expansion within the organ.
Subsequent mutational events would push progeny of this cell
down pathways towards full malignant transformation. However,
these events after the initial lesion would be independent. Unless
we analyse the primary alteration, subsequent investigation could
show that different epithelial areas (including the resultant tumour)
would possess different genetic alterations.
A second and perhaps a more simple explanation might be that
the tumour and abnormal margin epithelia represent completely
independent initiation events. In this hypothesis, the patient's lung
might contain numerous independent early lesions, as a conse-
quence of chronic and repeated exposure to the carcinogens
present in cigarette smoke. If we think of multiple, preneoplastic
epithelial areas scattered throughout the organ, then the data could
be interpreted to suggest that lesions with overexpression ofcyclin
Dl are less likely to progress to full malignancy. This surprising
idea arose in part from the consideration of four separate studies,
in which overexpression of CCNDI in tumours appeared to be
associated with a less aggressive phenotype or was a favourable
prognostic indicator (Betticher et al, 1996; Bringuier et al, 1996;
Gillett et al, 1996; Pelosio et al, 1996).
In conclusion, it would appear that aberrant expression ofcyclin
Dl and pRb, potentially resulting in the loss ofcontrol ofcell cycle
progression, could be early events in the development of NSCLC.
Further molecular investigations into the mechanisms resulting in
these alterations of gene expression in preneoplastic lesions are
warranted to define the significance of cyclin Dl and pRb
immunostaining of epithelial specimens obtained by bron-
choscopy, with the possibility that this finding is of importance in
the early diagnosis ofNSCLC.
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